French Association of Multiple Myeloma Patients (AF3M) is calling on health authorities to accelerate the approval of 5 new innovative medicines in the market this months

5 new molecules (carfilzomib, daratumumab, panobinostat, ixazomib and elotuzumab) have been shown to be effective at this stage of the disease. One of these promising drugs, carfilzomib (Kyprolis d'Amgen, already available) acts in a targeted way in the tumor cells, causing their destruction.

http://lequotidiendumedecin.fr